Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Friday

Janux Therapeutics (NASDAQ:JANX) is expected to be posting its quarterly earnings results before the market opens on Friday, March 14th. Analysts expect Janux Therapeutics to post earnings of ($0.49) per share for the quarter.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Price Performance

JANX stock opened at $31.81 on Thursday. The company’s 50 day simple moving average is $39.91 and its 200-day simple moving average is $47.17. The firm has a market capitalization of $1.88 billion, a P/E ratio of -27.19 and a beta of 3.23. Janux Therapeutics has a 52-week low of $28.92 and a 52-week high of $71.71.

Insider Transactions at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the sale, the chief executive officer now directly owns 217,054 shares in the company, valued at $12,196,264.26. This trade represents a 10.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the transaction, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 50,002 shares of company stock worth $2,684,703. Corporate insiders own 29.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Leerink Partners lifted their price target on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Wedbush restated an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank cut their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $88.00.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.